Dr. Eward on the Unmet Need for Novel Agents for TGCT and Sarcoma

William Eward, MD, DVM
Published: Thursday, Feb 13, 2020



William Eward, MD, DVM, associate professor and orthopedic surgical oncologist at Duke Cancer Institute, discusses the unmet need for novel agents in tenosynovial giant cell tumor (TGCT) and sarcoma.

Many drugs are under investigation in TGCT. Some trials are examining the use of immunotherapy in this space, specifically with pembrolizumab (Keytruda) in combination with radiation therapy. These studies are searching for a way to kill sarcoma cells.

Some drugs that have not been used in sarcoma might be effective in this space, such as those that target the proteasome and CRM1, says Eward. Some promising leads could help fill the unmet need in drug development that has existed since 1985, concludes Eward.
SELECTED
LANGUAGE


William Eward, MD, DVM, associate professor and orthopedic surgical oncologist at Duke Cancer Institute, discusses the unmet need for novel agents in tenosynovial giant cell tumor (TGCT) and sarcoma.

Many drugs are under investigation in TGCT. Some trials are examining the use of immunotherapy in this space, specifically with pembrolizumab (Keytruda) in combination with radiation therapy. These studies are searching for a way to kill sarcoma cells.

Some drugs that have not been used in sarcoma might be effective in this space, such as those that target the proteasome and CRM1, says Eward. Some promising leads could help fill the unmet need in drug development that has existed since 1985, concludes Eward.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x